Theratechnologies Announces the Exercise of the Over-Allotme
MONTREAL, CANADA--(Marketwired - July 31, 2015) - NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Theratechnologies Inc. ("Theratechnologies") (TSX:TH) today announced that it has received from the underwriters for its previously-announced offering of 4,000,000 units on an underwritten basis (the "Offering"), a notice of exercise in full of the option (the "Over-Allotment Option") granted to them to purchase 600,000 additional units (the "Over-Allotment Units") under the final short form prospectus dated July 30, 2015 (the "Prospectus"), at a price of $2.40 per Over-Allotment Unit. Each Over-Allotment Unit shall consist of one common share and one-half of a common share purchase warrant exercisable for a period of 24 months from the closing date of the Offering at an exercise price of $3.00 per share. The closing of the Offering and of the Over-Allotment Option is expected to occur concurrently, on or about August 6, 2015, and is subject to certain customary conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Toronto Stock Exchange. About Theratechnologies Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to promote healthy ageing and improved quality of life. Further information about Theratechnologies is available on Theratechnologies' website at www.theratech.com and on SEDAR at www.sedar.com.